Comerica Bank Has $112,000 Stock Position in scPharmaceuticals Inc. (NASDAQ:SCPH)

Comerica Bank raised its position in scPharmaceuticals Inc. (NASDAQ:SCPH) by 127.9% in the fourth quarter, HoldingsChannel reports. The fund owned 31,662 shares of the company’s stock after purchasing an additional 17,769 shares during the quarter. Comerica Bank’s holdings in scPharmaceuticals were worth $112,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the stock. King Luther Capital Management Corp lifted its position in shares of scPharmaceuticals by 28.4% during the 4th quarter. King Luther Capital Management Corp now owns 2,857,910 shares of the company’s stock valued at $10,117,000 after buying an additional 632,120 shares during the last quarter. Rice Hall James & Associates LLC raised its position in shares of scPharmaceuticals by 59.2% during the 4th quarter. Rice Hall James & Associates LLC now owns 989,635 shares of the company’s stock valued at $3,503,000 after buying an additional 367,970 shares in the last quarter. Nantahala Capital Management LLC grew its holdings in shares of scPharmaceuticals by 33.3% during the 4th quarter. Nantahala Capital Management LLC now owns 1,000,000 shares of the company’s stock valued at $3,540,000 after purchasing an additional 250,000 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of scPharmaceuticals by 16.7% during the 4th quarter. Geode Capital Management LLC now owns 750,493 shares of the company’s stock valued at $2,657,000 after purchasing an additional 107,151 shares during the last quarter. Finally, Raymond James Financial Inc. bought a new position in shares of scPharmaceuticals during the 4th quarter valued at $318,000. Hedge funds and other institutional investors own 89.52% of the company’s stock.

scPharmaceuticals Stock Performance

SCPH opened at $3.22 on Monday. The stock has a market capitalization of $169.99 million, a price-to-earnings ratio of -1.69 and a beta of 0.17. The company has a fifty day moving average of $2.60 and a 200 day moving average of $3.16. scPharmaceuticals Inc. has a fifty-two week low of $1.94 and a fifty-two week high of $5.65. The company has a debt-to-equity ratio of 1.66, a quick ratio of 6.89 and a current ratio of 8.08.

scPharmaceuticals (NASDAQ:SCPH) last released its earnings results on Wednesday, May 14th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.06). The firm had revenue of $11.75 million during the quarter, compared to the consensus estimate of $11.63 million. scPharmaceuticals had a negative return on equity of 244.93% and a negative net margin of 264.60%. As a group, sell-side analysts forecast that scPharmaceuticals Inc. will post -1.53 earnings per share for the current fiscal year.

Analysts Set New Price Targets

SCPH has been the topic of a number of research reports. HC Wainwright reaffirmed a “buy” rating and set a $18.00 target price on shares of scPharmaceuticals in a research note on Thursday, March 20th. Maxim Group dropped their target price on shares of scPharmaceuticals from $20.00 to $12.00 and set a “buy” rating on the stock in a research note on Thursday, March 20th.

About scPharmaceuticals

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.